We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live ... CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Show more
Ask ADVFN Intelligence (AI)
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and...
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.25 | 8.09643756747 | 27.79 | 30.09 | 27.63 | 679810 | 28.63390299 | CS |
| 4 | -4.2 | -12.2663551402 | 34.24 | 36.73 | 27 | 945784 | 30.46251772 | CS |
| 12 | -6.6 | -18.0131004367 | 36.64 | 40.47 | 27 | 594193 | 32.94373017 | CS |
| 26 | -0.48 | -1.57273918742 | 30.52 | 40.47 | 27 | 658897 | 34.62359621 | CS |
| 52 | 1.04 | 3.58620689655 | 29 | 50.23 | 25.77 | 677062 | 35.52312556 | CS |
| 156 | 1.04 | 3.58620689655 | 29 | 50.23 | 25.77 | 677062 | 35.52312556 | CS |
| 260 | 1.04 | 3.58620689655 | 29 | 50.23 | 25.77 | 677062 | 35.52312556 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
